Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

NCT07165769 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

Interventions

DRUG: Induction Therapy
DRUG: Maintenance Therapy

Sponsor

Institute of Hematology & Blood Diseases Hospital, China